Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-22
2011-03-22
McGarry, Sean (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07910725
ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes.
REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6107094 (2000-08-01), Crooke
patent: 7683166 (2010-03-01), McSwiggen et al.
patent: 2003/0064945 (2003-04-01), Akhtar et al.
patent: 2003/0083294 (2003-05-01), Sullenger et al.
patent: 2003/0190635 (2003-10-01), McSwiggen
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/14090 (1990-11-01), None
patent: WO-94/01550 (1994-01-01), None
patent: WO 99/13886 (1999-03-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/49029 (1999-09-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/44914 (2000-08-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-02/22636 (2002-03-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
GenBank Accession No. NM—001560, downloaded from http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=26787975, downloaded Sep. 9, 2004.
Callard et al. (Immunology Today, 1996 vol. 17:108-110).
Mintz et al. (Neoplasia, 2002 vol. 4:388-399).
Pieken et al. (Science, 1991, vol. 253: pp. 314-317).
Alexeev et al. “Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide,”Nature Biotech. 18:43-47 (2000).
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Bayard et al. “Increased stability and antiviral activity of 2′-O-phosphoglyceryl derivatives of (2′-5′)oligo(adenylate),”Eur. J. Biochem. 142:291-298 (1984).
Bertrand et al. “Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo,” Biochem. Biophys. Res. Comm. 296:10004-1004 (2002).
Braasch et al. “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,”Biochem. 41(14):4503-4510 (2002).
Caplen “RNAi as a gene therapy approach,”Expert Opin. Biol. Ther. 3(4):575-586 (2003).
Crooke et al. “Kinetic characteristics ofEscherichia coliRNase H1: cleavage of various antisense oligonucleotide-RNA duplexes,”Biochem. 312:599-608 (1995).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
Hammond et al. “An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells,”Nature404:293-296 (2000).
Hammond et al. “Post-Transcriptional Gene Silencing by Double-Stranded RNA,”Nature2:110-119 (2001).
Jen et al. “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,”Stem Cells18:307-319 (2000).
Kurreck et al. “Design of antisense oligonucleotides stabilized by locked nucleic acids,”Nucl. Acids Res. 30(9):1911-1918 (2002).
Olie et al. “Analysis of Ribosyl-Modified, Mixed Backbone Analogs of a bcl-2/bcl-xL Antisnesne Oligonucleotide,”Biochim. Biophys.Acta1576:101-109 (2002).
Parrish et al. “Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference,”Mol. Cell6:1077-1087 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Nov. 1, 2006 for U.S. Appl. No. 10/922,675, 19 pages.
Beigelman Leonid
McSwiggen James
Gibbs Terra Cotta
Ginkel Laura M.
McGarry Sean
Muthard David A.
Sirna Therapeutics, Inc.
LandOfFree
RNA interference mediated inhibition of interleukin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of interleukin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of interleukin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757299